Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Revenue (2016 - 2025)

Historic Revenue for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $115.5 million.

  • Ligand Pharmaceuticals' Revenue rose 12284.61% to $115.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $251.2 million, marking a year-over-year increase of 6482.73%. This contributed to the annual value of $167.1 million for FY2024, which is 2727.74% up from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Revenue is $115.5 million, which was up 12284.61% from $47.6 million recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Revenue peaked at $115.5 million during Q3 2025, and registered a low of $26.4 million during Q2 2023.
  • Moreover, its 5-year median value for Revenue was $46.6 million (2021), whereas its average is $49.7 million.
  • Its Revenue has fluctuated over the past 5 years, first tumbled by 4740.06% in 2023, then skyrocketed by 12284.61% in 2025.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Revenue stood at $56.4 million in 2021, then dropped by 10.68% to $50.4 million in 2022, then plummeted by 44.22% to $28.1 million in 2023, then surged by 52.35% to $42.8 million in 2024, then surged by 169.69% to $115.5 million in 2025.
  • Its Revenue stands at $115.5 million for Q3 2025, versus $47.6 million for Q2 2025 and $45.3 million for Q1 2025.